Department of Radiation Oncology, University of Oklahoma Health Sciences Center, BMSB 311, 940 Stanton L. Young Boulevard, Oklahoma City, OK, 73104, USA.
Stephenson Cancer Center, Oklahoma City, OK, USA.
Cell Biol Toxicol. 2023 Jun;39(3):1053-1076. doi: 10.1007/s10565-021-09663-4. Epub 2021 Oct 9.
Neuroblastoma (NB) progression is branded with hematogenous metastasis and frequent relapses. Despite intensive multimodal clinical therapy, outcomes for patients with progressive disease remain poor, with negligible long-term survival. Therefore, understanding the acquired molecular rearrangements in NB cells with therapy pressure and developing improved therapeutic strategies is a critical need to improve the outcomes for high-risk NB patients. We investigated the rearrangement of MMP9 in NB with therapy pressure, and unveiled the signaling that facilitates NB evolution. Radiation-treatment (RT) significantly increased MMP9 expression/activity, and the induced enzyme activity was persistently maintained across NB cell lines. Furthermore, RT-triggered NFκB transcriptional activity and this RT-induced NFκB were required/adequate for MMP9 maintenance. RT-triggered NFκB-dependent MMP9 actuated a second-signaling feedback to NFκB, facilitating a NFκB-MMP9-NFκB positive feedback cycle (PFC). Critically, MMP9-NFκB feedback is mediated by MMP9-dependent activation of IKKβ and ERK phosphotransferase activity. Beyond its tumor invasion/metastasis function, PFC-dependent MMP9 lessens RT-induced apoptosis and favors survival pathway through the activation of NFκB signaling. In addition, PFC-dependent MMP9 regulates 19 critical molecular determinants that play a pivotal role in tumor evolution. Interestingly, seven of 19 genes possess NFκB-binding sites, demonstrating that MMP9 regulates these molecules by activating NFκB. Collectively, these data suggest that RT-triggered NFκB-dependent MMP9 actuates feedback to NFκB though IKKβ- and ERK1/2-dependent IκBα phosphorylation. This RT-triggered PFC prompts MMP9-dependent survival advantage, tumor growth, and dissemination. Targeting therapy-pressure-driven PFC and/or selective inhibition of MMP9 maintenance could serve as promising therapeutic strategies for treatment of progressive NB.
神经母细胞瘤(NB)的进展以血行转移和频繁复发为特征。尽管采用了强化的多模式临床治疗,但进展性疾病患者的预后仍然很差,长期生存几乎不存在。因此,了解 NB 细胞在治疗压力下获得的分子重排,并开发改进的治疗策略,是改善高危 NB 患者预后的当务之急。我们研究了治疗压力下 NB 中 MMP9 的重排,并揭示了促进 NB 进化的信号。放射治疗(RT)显著增加了 MMP9 的表达/活性,并且诱导的酶活性在 NB 细胞系中持续保持。此外,RT 触发的 NFκB 转录活性和这种 RT 诱导的 NFκB 对于 MMP9 的维持是必需的/充分的。RT 触发的 NFκB 依赖性 MMP9 激活了第二信号反馈到 NFκB,促进了 NFκB-MMP9-NFκB 正反馈循环(PFC)。至关重要的是,MMP9-NFκB 反馈是由 MMP9 依赖性激活 IKKβ 和 ERK 磷酸转移酶活性介导的。除了其肿瘤侵袭/转移功能外,PFC 依赖性 MMP9 通过激活 NFκB 信号减少 RT 诱导的细胞凋亡,并通过激活 NFκB 信号促进存活途径。此外,PFC 依赖性 MMP9 调节 19 个关键分子决定因素,这些因素在肿瘤进化中起着关键作用。有趣的是,19 个基因中有 7 个具有 NFκB 结合位点,表明 MMP9 通过激活 NFκB 来调节这些分子。总的来说,这些数据表明,RT 触发的 NFκB 依赖性 MMP9 通过 IKKβ 和 ERK1/2 依赖性 IκBα磷酸化作用于 NFκB。这种 RT 触发的 PFC 促使 MMP9 依赖性生存优势、肿瘤生长和扩散。针对治疗压力驱动的 PFC 和/或选择性抑制 MMP9 维持可能成为治疗进展性 NB 的有前途的治疗策略。